Leah Lawrence, Author at Cancer Therapy Advisor

Higher Body Fat Linked to Higher Risk of Death From Prostate Cancer

By

Leah Lawrence

May 19, 2022

Increases in waist-to-hip ratio, body mass index, waist circumference, and total body fat percentage were associated with increases in the risk of prostate cancer death.

General Oncology

AYA Cancer Survivors Twice As Likely to Die From Second Cancer

By

Leah Lawrence

May 17, 2022

The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.

General Oncology

Younger Cancer Patients May Be at High Risk of Death From COVID-19

By

Leah Lawrence

May 16, 2022

Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.

Gastrointestinal Cancers

Improved Survival Supports Routine Use of Laparoscopic Surgery for Rectal Cancer

By

Leah Lawrence

May 12, 2022

A meta-analysis showed a significant improvement in overall survival, but not disease-free survival, with laparoscopic surgery.

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.

General Oncology

Molecular Profiling Can Guide Treatment After Recurrence in Young Cancer Patients

By

Leah Lawrence

May 11, 2022

Nearly 70% of patients had at least 1 potentially actionable therapeutic target.

AACR 2022

Adebrelimab Improves PFS, OS in Extensive-Stage Small Cell Lung Cancer

By

Leah Lawrence

April 15, 2022

Adding adebrelimab to chemotherapy nearly doubled the 2-year overall survival rate and more than tripled the 1-year progression-free survival rate.

AACR 2022

Pandemic Exacerbates Disparities in Outcomes for Pediatric Cancer Patients

By

Leah Lawrence

April 14, 2022

Pediatric cancer patients in low- and middle-income countries had a nearly 16-fold higher risk of all-cause mortality within 30 days of presentation, when compared with their counterparts in high-income countries.

AACR 2022

RACE Act Increases Required Pediatric Studies for Cancer Drugs

By

Leah Lawrence

April 13, 2022

In the year before the RACE Act was implemented, none of the approved therapies required pediatric study, but 92% of them had a mechanism of action that would necessitate pediatric studies under the RACE Act.